TY - JOUR
T1 - Tumor immunity meets autoimmunity
T2 - Antigen levels and dendritic cell maturation
AU - Spiotto, Michael T.
AU - Fu, Yang Xin
AU - Schreiber, Hans
N1 - Funding Information:
The authors regret that page limits prevent the citation and discussion of all of the work in this area and apologize to those whose original and seminal work has not been referenced as a result. H.S. would like to acknowledge the financial support of National Institutes of Health grants RO1-CA22677, RO1-CA37516, PO1-CA97296 and by the University of Chicago Cancer Research Center CA-14599. MTS is a recipient of the training grant HD 07009.
PY - 2003/12
Y1 - 2003/12
N2 - Naïve T cells in the draining lymph node (DLN) do not immediately respond to antigenic tissues or antigenic cancers in the periphery. Rather, the conditions under which naïve T cells encounter antigen in the DLN can result in the distinct immunological states of ignorance, tolerance or immunity. Recent work suggests that these immunological states are determined by the level of antigen expressed by peripheral tissues and the maturation stage of the dendritic cell presenting the antigen. When antigens are expressed at levels that are sufficient to be cross-presented by mature dendritic cells in the DLN, naïve T cells can respond to self antigens or tumor antigens to induce a state of autoimmunity or tumor immunity, respectively. Exploiting these conditions to target unique tumor antigens will enable us to develop better cancer immunotherapies.
AB - Naïve T cells in the draining lymph node (DLN) do not immediately respond to antigenic tissues or antigenic cancers in the periphery. Rather, the conditions under which naïve T cells encounter antigen in the DLN can result in the distinct immunological states of ignorance, tolerance or immunity. Recent work suggests that these immunological states are determined by the level of antigen expressed by peripheral tissues and the maturation stage of the dendritic cell presenting the antigen. When antigens are expressed at levels that are sufficient to be cross-presented by mature dendritic cells in the DLN, naïve T cells can respond to self antigens or tumor antigens to induce a state of autoimmunity or tumor immunity, respectively. Exploiting these conditions to target unique tumor antigens will enable us to develop better cancer immunotherapies.
UR - http://www.scopus.com/inward/record.url?scp=0242575283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242575283&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2003.09.018
DO - 10.1016/j.coi.2003.09.018
M3 - Review article
C2 - 14630209
AN - SCOPUS:0242575283
SN - 0952-7915
VL - 15
SP - 725
EP - 730
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 6
ER -